Study: brain-computer interface company Science Corp.'s PRIMA device, comprised of a retinal implant and special glasses, restored vision in some blind patients
www.bbc.com/news/article... @heib20 : Oh wow! 👏👏✨ This is absolutely awesome! What a life-changing achievement! ⭐️ — www.bbc.com/news/article... @platogue : Yes, doctor, I can see you now! — Awesome! 💙🍀🙏🌻🫂🌥️⛅🦋🐝🐦🐿️🌈💕 Emma Zhou / @emmz : new england journal of medicine published the results of our clinical trial! 🧪 — www.bbc.com/news/article... Mastodon: Natasha Jay / @Natasha_Jay@tech.lgbt : For just once have some flat out good news that will make the world better — “Life-changing eye implant helps blind patients read again” — https://www.bbc.com/... #Science #News Forums: r/news : Life-changing eye implant helps blind patients read again r/worldnews : Life-changing eye implant helps blind patients read again
MIT Technology ReviewAntonio Regalado
Context & Ripple Effects
Science Corp. had previously reported that its retinal implant enabled some people to read, play cards and recognize faces; the newly published clinical results add formal study evidence to that earlier patient-function claim.
The story also sits against a cautionary precedent: users of Second Sight retinal implants faced loss of support as the technology aged, underscoring that an implanted vision system is a long-term service commitment, not only a clinical product when artificial-vision support became uncertain.
First-order effects
The published results strengthen the clinical case for Science Corp.’s implant-and-glasses system among patients with the studied form of blindness and the clinicians evaluating it.
Science Corp. gains study-backed validation for PRIMA rather than relying solely on company-reported demonstrations.
Second-order effects
Competing retinal-prosthesis developers will face greater pressure to show comparable patient outcomes, not just technical feasibility.
Hospitals and prospective users will scrutinize the full care model—implant procedure, external glasses, follow-up and device support—alongside the reported vision benefit.
Third-order effects
If replicated across broader use, retinal implants could shift from experimental demonstrations toward a specialized, evidence-led medical-device category whose value depends on durable post-implant support.
The Second Sight experience suggests that long-term maintenance, upgrade paths and manufacturer continuity may become as consequential to adoption as initial visual performance.
The trend: Brain-computer-interface companies are increasingly being judged by peer-reviewed, patient-level outcomes and the durability of the care systems behind implanted devices.
As we wrote earlier this summer, we've submitted PRIMA for market approval in Europe and are currently in the review process there: https://science.xyz/... We're also engaged with US FDA on the next steps to bring PRIMA to more patients here
Neuralink competitor Science Corp. is on track to beat Elon to a brain-interface product after acquiring a retinal implant program at a fire sale price of 4mm Euros. https://www.technologyreview.com/ ...
🚨 Incredible white pill 🚨 a micro-retinal implant just restored sight in people who were completely blind from macular degeneration! in the clinical trial 81 % of patients regained clinically meaningful vision not full natural sight yet, but it's the first clear proof that [image…
Thank you to @GinaKolata @NYTimes for their thoughtful reporting on @NEJM's new paper on the results of our landmark clinical trial of our PRIMA retinal implant https://www.nytimes.com/...
Presented at #AAO2025: In persons with geographic atrophy due to age-related macular degeneration, a neurostimulation system composed of glasses, a processor, and a subretinal implant restored central vision and significantly improved visual acuity. Full PRIMAvera study: [image]
The New England Journal of Medicine (@NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial of our PRIMA brain-computer interface (BCI) retinal implant. [video]
Very excited that the clinical trial results for our PRIMA retinal prosthesis are published today in the New England Journal of Medicine! This is the first time that patients who are blind due to photoreceptor loss have been able to intuitively see again. [image]